Skip to main
BDSX

Biodesix (BDSX) Stock Forecast & Price Target

Biodesix (BDSX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biodesix is a commercial-stage diagnostics company focused primarily on lung diseases and their diagnosis. With a focused, multi-omic pure-play in this space, including proprietary AI technology and a suite of blood-based tests that address immediate clinical needs, the company has demonstrated strong revenue growth and increasing gross margins. Additionally, the company's Development Services segment serves not just as a revenue generator, but also as a source of valuable biological insights for the company's pipeline. However, potential factors that could impact Biodesix's future growth include payor concentration risks, ongoing market education efforts for its tests, and the volatility and uncertainty surrounding reimbursement rates and commercial payor coverage decisions.

Bears say

Biodesix is heavily dependent on Medicare reimbursement, has limited access to capital as a small public company, and faces significant competition in other areas of diagnostic testing. Additionally, the company has reported negative operating cash flows and may have difficulty achieving and sustaining profitability. These factors contribute to my negative outlook on Biodesix's stock.

Biodesix (BDSX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biodesix (BDSX) Forecast

Analysts have given Biodesix (BDSX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Biodesix (BDSX) has a Strong Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biodesix (BDSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.